BridgeBio Pharma, Inc. (NASDAQ:BBIO) is Sphera Funds Management LTD.'s 2nd Largest Position

Sphera Funds Management LTD. boosted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 7.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 905,279 shares of the company's stock after acquiring an additional 62,635 shares during the quarter. BridgeBio Pharma comprises about 4.5% of Sphera Funds Management LTD.'s investment portfolio, making the stock its 2nd biggest position. Sphera Funds Management LTD. owned 0.48% of BridgeBio Pharma worth $24,841,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC increased its stake in BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after acquiring an additional 472 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in BridgeBio Pharma during the fourth quarter worth approximately $41,000. Sterling Capital Management LLC boosted its position in shares of BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock valued at $49,000 after buying an additional 1,514 shares during the period. Avanza Fonder AB purchased a new position in shares of BridgeBio Pharma during the fourth quarter valued at approximately $181,000. Finally, First Bank & Trust purchased a new position in shares of BridgeBio Pharma during the fourth quarter valued at approximately $205,000. 99.85% of the stock is owned by institutional investors.

BridgeBio Pharma Trading Down 0.4%

Shares of NASDAQ BBIO traded down $0.15 during trading hours on Monday, reaching $33.69. The stock had a trading volume of 2,392,360 shares, compared to its average volume of 2,437,165. The firm has a market cap of $6.40 billion, a price-to-earnings ratio of -11.82 and a beta of 1.15. The business's fifty day moving average price is $34.43 and its two-hundred day moving average price is $31.65. BridgeBio Pharma, Inc. has a 52-week low of $21.62 and a 52-week high of $39.54.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.12. The firm had revenue of $36.74 million during the quarter, compared to analysts' expectations of $57.14 million. The firm's revenue for the quarter was down 44.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.20) EPS. Equities research analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BBIO. JPMorgan Chase & Co. boosted their target price on BridgeBio Pharma from $44.00 to $50.00 and gave the company an "overweight" rating in a research report on Monday, March 24th. HC Wainwright boosted their target price on BridgeBio Pharma from $49.00 to $53.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. Cantor Fitzgerald restated an "overweight" rating and set a $95.00 target price on shares of BridgeBio Pharma in a research report on Friday, February 21st. Redburn Atlantic began coverage on BridgeBio Pharma in a research report on Monday, March 31st. They set a "buy" rating and a $50.00 target price for the company. Finally, Piper Sandler boosted their target price on BridgeBio Pharma from $46.00 to $63.00 and gave the company an "overweight" rating in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat.com, BridgeBio Pharma presently has a consensus rating of "Moderate Buy" and a consensus price target of $57.09.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, CEO Neil Kumar sold 31,543 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $36.14, for a total transaction of $1,139,964.02. Following the sale, the chief executive officer now owns 211,718 shares of the company's stock, valued at approximately $7,651,488.52. This trade represents a 12.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Brian C. Stephenson sold 4,148 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $36.16, for a total value of $149,991.68. Following the sale, the chief financial officer now directly owns 102,464 shares in the company, valued at $3,705,098.24. This trade represents a 3.89% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,410,217 shares of company stock valued at $417,634,332. 18.20% of the stock is currently owned by corporate insiders.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.